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Abstract 
Purpose Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast 
cancer. It is unclear, however, whether this association is due to shared genetic factors. 
Methods  We constructed a genetic risk score (GRS) using risk variants from 33 known independent T2D 
susceptibility loci and evaluated its relation to breast cancer risk using the data from two consortia, including 
62,328 breast cancer patients and 83,817 controls of European ancestry. Unconditional logistic regression 
models were used to derive adjusted odds ratios (OR) and 95% confidence intervals (CI) to measure the 
association of breast cancer risk with T2D GRS or T2D-associated genetic risk variants. Meta-analyses were 
conducted to obtain summary ORs across all studies. 
Results  The T2D GRS was not found to be associated with breast cancer risk, overall, by menopausal 
status, or for estrogen receptor positive or negative breast cancer. Three T2D associated risk variants were 
individually associated with breast cancer risk after adjustment for multiple comparisons using the Bonferroni 
method (at P < 0.001), rs9939609 (FTO) (OR = 0.94, 95% CI = 0.92 – 0.95, P = 4.13E-13), rs7903146 (TCF7L2) 
(OR = 1.04, 95% CI = 1.02 – 1.06, P = 1.26E-05), and rs8042680 (PRC1) (OR = 0.97, 95% CI = 0.95 – 0.99, 
P = 8.05E-04). 
Conclusions  We have shown that several genetic risk variants were associated with the risk of both T2D and 
breast cancer. However, overall genetic susceptibility to T2D may not be related to breast cancer risk.  
Key words: type 2 diabetes, genetic susceptibility, GWAS, breast cancer, epidemiology 
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Introduction 
Globally, approximately 382 million people currently live with diabetes, and this number may rise to 
592 million by 2035 [1]. Type 2 diabetes (T2D), accounts for over 90% of all diabetes cases [2]. Breast cancer is 
the most common cancer among women in many countries, including the United States [3]. Many 
epidemiological studies have linked T2D to increased breast cancer risk [4-8]. Recent meta-analyses have 
shown a more than 20% increase in risk of breast cancer among women with T2D compared to women 
without the disease [9-12]. T2D and breast cancer share some risk factors, including obesity in 
postmenopausal women and physical inactivity [13]. Elevated levels of circulating C-peptide and insulin-like 
growth factor-1, biomarkers related to insulin resistance, have also been associated with increased breast 
cancer risk [14,15]. It remains unclear, however, if the link between these two diseases is due to shared 
lifestyle risk factors or intrinsic etiology such as genetic susceptibility. Understanding how genetic variants 
related to T2D risk influence breast cancer risk may provide insights into the nature of the T2D-breast cancer 
relationship. 
Recent genome-wide association studies (GWAS) have identified approximately 50 genetic variants 
associated with T2D risk. Some of these reported T2D-related genetic variants have been studied in relation to 
the risk of several cancers, including cancers of the pancreas [16], colon/rectum [17,18] and prostate [19]. The 
influence of these variants on breast cancer risk, however, has not been adequately studied. To date, only two 
studies have evaluated the association of a subset of these T2D-related genetic variants with breast cancer risk 
[20,21]. Both studies reported a null association, which may be due to small study size and low study power.  
In this analysis, using data from two consortia including 62,328 breast cancer cases and 83,817 controls 
of women of European ancestry, we evaluated T2D-related genetic variants reported to date in relation to 
breast cancer risk. By constructing a T2D-related genetic risk score (T2D GRS) and evaluating its association 
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with breast cancer risk, we tested the hypothesis that, overall, the alleles that increase T2D risk may also 
increase breast cancer risk. We also tested the hypothesis that certain T2D-related genetic variants may be 
associated with breast cancer risk.  
Methods 
Study population  
Included in this analysis were 62,328 breast cancer cases and 83,817 controls of women of European 
ancestry recruited either in the 39 studies (Online Resource Table 1) that participated in the Breast Cancer 
Association Consortium (BCAC), a part of the Collaborative Oncological Gene-Environment Study (COGS), or in 
the eleven studies (Online Resource Table 2) that are included in the Discovery, Biology, and Risk of Inherited 
Variants in Breast Cancer (DRIVE) project of Genetic Associations and Mechanism in Oncology (GAME-ON). 
From the BCAC, we included individual-level data for 46,325 breast cancer cases and 42,482 controls. The 
DRIVE project included 16,003 breast cases and 41,335 controls; however, only summary statistics for the 
association between T2D-related risk variants and breast cancer risk were available, and thus these summary 
statistics were used in our study. The study samples and participant data, including demographics and the 
traditional risk factors for breast cancer, were collected in each contributing study. 
Single nucleotide polymorphism (SNP) selection 
We searched for all reported genetic risk variants associated with T2D in European ancestry 
populations at a genome-wide significance level (P < 5 × 10-8 , trait “Type 2 diabetes” or “Type 2 diabetes and 
other traits”) using the US National Human Genome Resource Institute (NHGRI) Catalog of Published Genome-
Wide Association Studies (GWAS Catalog, accessed November 19, 2012, at 
http://www.genome.gov/gwastudies). Fifty SNPs representing 33 independent loci (linkage disequilibrium (LD) 
R2 < 0.1) were identified (Fig. 1). 
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Genetic risk score construction 
The genetic risk scores were calculated in 46,325 cases and 42,482 controls included in the BCAC. At 
each of the 33 independent loci, we selected the SNP with the lowest P-value for association with T2D 
reported in GWASs to represent the locus in constructing the T2D GRS. Using these 33 SNPs, a weighted T2D 
GRS was constructed as a measure of the overall association of genetic risk variants with T2D. In the BCAC, 
eleven SNPs were directly genotyped and 22 were imputed with imputation quality threshold of R2 > 0.5. The 
T2D GRS was created as ∑ 𝑤𝑖𝑆𝑁𝑃𝑖
33
𝑖  , where 𝑤𝑖 is the logarithm of the odds ratio (OR) of the i
th SNP with T2D 
reported from previous GWAS, and 𝑆𝑁𝑃𝑖  is the number of risk alleles carried by a given subject on the i
th SNP. 
We hypothesized that the risk allele for T2D would be associated with increased risk of breast cancer. The 33 
individual T2D risk variants identified from the NHGRI GWAS catalog are presented in Online Resource Table 3. 
Genotyping 
In the BCAC, genotype data were obtained either from direct genotyping with a custom Illumina iSelect 
genotyping array (iCOGS) that contains 211,155 SNPs [22] or from imputation with the 1000 Genomes Project 
Phase I integrated variant set (version 3, March 2012 release) as the reference [23], using the program 
IMPUTE2 [24]. Details of the studies that participated in the BCAC, and the methodology used by the BCAC 
and iCOGS have been published elsewhere [22] and can also be found on the iCOGS website 
(http://ccge.medschl.cam.ac.uk/research/consortia/icogs/). 
In the DRIVE project, genotype data were obtained either from direct genotyping using Illumina or 
Affymetrix arrays (Online Resource Table 2) or from imputation with the HapMap version 2 CEU panel (Utah 
residents of Northern and Western European ancestry) as a reference, using the program MACH v1.0 or 
IMPUTE [24]. Details of the studies that participated in DRIVE were described in previously published papers 
[22,25-28] or on the GAME-ON website (http://gameon.dfci.harvard.edu). 
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Statistical analysis 
We evaluated the association between the T2D GRS and breast cancer risk using individual-level data 
from 46,325 breast cancer cases and 42,482 controls of European ancestry who participated in BCAC studies. 
Demographic characteristics and known breast cancer risk factors were summarized by case-control status 
using mean and standard deviation (SD) for continuous variables or frequency with percentage for categorical 
variables. Differences between cases and controls were compared using the Wilcoxon rank sum test 
(continuous variables) or the χ2 test (categorical variables). To assess the association between the T2D GRS 
and breast cancer risk factors, we used control data and calculated the mean and SD of the T2D GRS by 
comparison groups for each categorical variable; the difference was tested by the Wilcoxon rank sum test. For 
continuous variables, the Pearson’s correlations were measured. To account for potential population 
stratification within our study population, genetic ancestry was estimated by principal component (PC) 
analysis using EIGENSTRAT software [29] on 37,000 uncorrelated SNPs (including those selected as ancestry 
informative markers) on the chip. The mean value of the genomic inflation factor (λ) was 1.01 for the 
participating studies when PCs were included in the regression models, indicating little evidence of population 
stratification [22]. For all analyses, the top eight PCs were included in all regression models. For the LMBC 
study, the study-specific principal component was further adjusted. To assess the association between the 
T2D GRS and breast cancer risk, we first fitted unconditional logistic regression models adjusting for age and 
PCs within each of the 39 contributing studies individually and recorded the β coefficients with standard errors 
for T2D GRS quintiles (relative to the first quintile). We then conducted a meta-analysis on the results from 
these 39 studies using both fixed effect and mixed effect models. The odds ratios (ORs) with 95% confidence 
intervals (CI) from the fixed effects model are reported in Table 1, as are further analyses by estrogen receptor 
(ER) status, menopausal status, age group (<50 vs. ≥50 years), and body mass index (BMI, <25 vs. ≥25 kg/m2).  
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We also used the SNP-set Kernel Association Test (SKAT) to evaluate whether any SNP in the T2D-
associated SNP set may be related to breast cancer risk without making the assumption that the alleles that 
increase T2D risk may also increase breast cancer risk [30]. To evaluate the association of each individual SNP 
(per copy of risk allele) with breast cancer risk, we used individual-level data from the BCAC (46,325 cases and 
42,482 controls) and summary results data from DRIVE (16,003 cases and 41,335 controls). We first estimated 
allelic OR for each SNP for each BCAC study with adjustment similar to that in the analyses for the association 
of T2D GRS with breast cancer risk described above and then combined the results across all BCAC studies 
with results from DRIVE using the inverse-variance meta-analysis with a fixed-effect model. Both consortium-
specific results and combined results are reported in Table 2. For individual SNP analyses, statistical 
significance was considered after adjusting for multiple comparisons using the Bonferroni method (0.05/33). 
For all other analyses, statistical significance was considered at a two-sided 5% level unless stated otherwise. 
All analyses were conducted using R version 3.0.3 [31]. 
Results 
Among the 88,807 BCAC participants studied, on average, cases were slightly older than controls (57.8 
vs. 54.9 years, P < 0.001) and entered menopause at a younger age (48.5 vs. 48.7 years, P < 0.01), as shown in 
Online Resource Table 4. More cases than controls were postmenopausal (69.3% vs. 68.1%, P < 0.01) or had a 
first-degree family history of breast cancer (27.7% vs. 11.2%, P < 0.01). Among postmenopausal women, cases 
and controls had comparable BMI (P = 0.62). Among controls, the T2D GRS was positively correlated with BMI 
(postmenopausal women, Pearson r = 0.018, P = 0.03), and inversely correlated with age at menarche 
(Pearson r = -0.021, P < 0.01). For other categorical variables examined, the mean T2D GRS values were 
virtually identical across different statuses (Online Resource Table 4, right columns).  
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Overall, the T2D GRS was not found to be associated with breast cancer risk (P for trend = 0.69, Table 
1). No significant results were observed in analyses stratified by ER status (P for trend = 0.74 and 0.47 for ER+ 
and ER- breast cancer, respectively), menopausal status (P for trend = 0.74 and 0.93 for premenopausal and 
postmenopausal women, respectively), age group (P for trend = 0.74 and 0.62 for age<50 and age≥50 years, 
respectively), or BMI group (P for trend = 0.64 and 0.64 for BMI<25 and BMI≥25, respectively). Meta-analysis 
using mixed effect models gave similar results (data not shown). In a sensitivity analysis, which included only 
the eleven directly genotyped SNPs and 14 imputed SNPs with imputation R2 > 0.9, similar results were 
observed (Online Resource Table 5).  
Using SKAT tests and without making the assumption that the alleles that increase T2D risk also 
increase breast cancer risk, we found evidence for potential association for some of the T2D-related SNPs with 
breast cancer risk (P = 3.95E-10). Of the 33 independent SNPs investigated, seven were nominally associated 
with breast cancer risk using BCAC data alone (Table 2). Of these, the risk allele for T2D in four SNPs was 
associated with a reduced risk of breast cancer. After adjusting for multiple comparisons, the association for 
two SNPs, rs7903146 (TCF7L2, OR = 1.04, 95% CI = 1.02 – 1.07, P = 1.20E-04) and rs9939609 (FTO, OR = 0.93, 
95% CI = 0.91 – 0.95, P = 3.63E-12), remained statistically significant, and both associations were replicated in 
DRIVE. SNP rs8042680 (PRC1) was related to breast cancer risk in the BCAC at P = 0.02 and in DRIVE at 
P = 6.18E-3; meta-analyses of these data yielded a significant association after adjusting for multiple 
comparisons (OR = 0.97, 95% CI = 0.99 – 0.99, P = 8.05E-4). 
Discussion 
In this large study, we investigated the association of 33 independent T2D related genetic variants with 
breast cancer risk individually and in combination (through the use of our GRS). Generally, we found no 
association between T2D GRS and risk of breast cancer overall or by ER status. Of the 33 T2D-associated SNPs 
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investigated in this study, three showed a significant association with breast cancer risk after adjusting for 
multiple comparisons: rs9939609 (FTO), rs7903146 (TCF7L2), and rs8042680 (PRC1). Although this study does 
not provide any evidence for an overall association of T2D susceptibility and breast cancer risk, it does show 
that some T2D-associated SNPs may be related to breast cancer risk. 
It has been hypothesized that the association between T2D and breast cancer may be mediated 
through insulin resistance and hyperinsulinaemia [32]. T2D and breast cancer share some lifestyle risk factors, 
including obesity in postmenopausal women and physical inactivity. Indeed, it has been shown previously that 
the observed association between these two diseases may be, in part, due to residual confounding by BMI 
[33]. With a very large sample size, our study suggests that overall genetic susceptibility to T2D was not 
related to breast cancer risk, indicating that the previously observed association between T2D and breast 
cancer risk may be largely due to shared lifestyle risk factors. Our finding for a null association between T2D 
GRS and breast cancer risk is supported by two previous studies that investigated this association. In one of 
these studies, Chen et al. investigated 18 T2D-related SNPs among 503 European ancestry cases and 633 
controls from the multiethnic cohort and PAGE studies [20]. In the other study, Hou et al. pooled data for 25 
genotyped and 15 imputed T2D-related SNPs from seven studies and investigated this association among 
1,142 European ancestry cases and 1,137 European ancestry controls [21]. Neither study reported a significant 
association between T2D GRS and overall breast cancer risk. However, these two studies had evaluated a 
smaller set of T2D risk variants than the current study and the sample size in both studies was substantially 
smaller than the current study, and thus the statistical power in these two previous studies was low. For 
example, for a given SNP with a minor allele frequency of 0.3, the current study had 99.6% power to detect an 
OR of 1.05 at a type I error rate of 0.05, while, the previous studies had <15% power to detect an OR of 1.05. 
We identified three T2D risk variants that were associated with breast cancer risk. SNPs in strong 
correlation with each of these three variants have recently been identified in GWAS to be associated with 
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breast cancer risk. SNP rs9939609 (FTO) located in region 16q12.2, and rs7903146 (TCF7L2) located in region 
10q25.2 are in perfect LD (R2 = 1) with rs17817449 and rs7904519, respectively, which were identified in 
relation to breast cancer risk in a GWAS conducted using BCAC data [22]. SNP rs8042680 (PRC1) is in strong LD 
with rs2290203 (R2 = 0.59, 9,270bp apart) that was recently identified as a risk variant for breast cancer in a 
GWAS conducted in East Asian women [34]. Interestingly, the T2D-risk allele of rs9939609 and rs8042680 are 
associated with a decreased risk of breast cancer. Though studies have suggested that TCF7L2 may associate 
with breast cancer through the wnt/β-catenin pathway [35,36], the exact mechanisms underlying these 
associations are unclear. Further studying these genes may uncover additional insights into the biology and 
genetics that link the risk of breast cancer and T2D. 
The sample size for our study was very large. When comparing subjects in T2D GRS Q5 to those in Q1, 
our study had 80% power to detect an OR for breast cancer risk as low as 1.06 (or 0.94) at 5% type I error rate.  
Our study showed that the association between T2D GRS and breast cancer risk should be very small, if it 
exists. The GRS used in our study was constructed using SNPs with established association with T2D, as 
demonstrated convincingly in previous GWAS, and thus this GRS should have a clear association with T2D. 
Indeed, using the resources from the Nashville Breast Health Study [37], we showed that this GRS was related 
to T2D in a dose-response manner (P for trend < 0.01, Online Resource Table 6). However, there are some 
potential limitations of our study. The T2D treatment information was not available for the study, preventing 
us from conducting an in-depth evaluation of the potential influence of T2D treatment on the association of 
T2D risk variants with breast cancer risk. To reduce potential influence of T2D treatment, we conducted an 
analysis among younger patients (< 50 years old) who are less likely to have T2D diagnosis than the older age 
group. This analysis showed similar results in younger and older groups (Table 2), indicating that the influence 
of T2D treatment on the association of T2D risk variants with breast cancer risk should be small. 
Approximately two-thirds of the SNPs used to construct the T2D GRS were not directly genotyped. We 
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imputed these SNPs using 1000 Genomes Project data as the reference. The imputation quality was high. In a 
sensitivity analysis, we constructed an alternate T2D GRS using only the 11 directly genotyped SNPs and the 14 
imputed SNPs which had almost perfect quality (R2 > 0.9). This T2D GRS is highly correlated with the T2D GRS 
used in our primary analysis (Pearson’s r = 0.93) and using the alternate T2D GRS did not change the results 
appreciably. Since we started this project, 14 new genetic loci for T2D have been identified. Unfortunately, we 
don’t have any data for these 14 new loci for our study. However, the strength of the association of T2D risk is 
much weaker for these newly identified variants than the 33 variants identified previously and included in our 
study. Therefore, we believe that including these variants would not change the conclusion of this study. 
Finally, all participants in this study are of European ancestry, possibility affecting the generalizability of our 
study findings to other populations.  
In conclusion, our study found no apparent association between a polygenetic score constructed using 
the known T2D risk variants identified to date in GWAS and breast cancer risk among women of European 
ancestry. It is possible that the previously reported association between these two diseases could be due to 
shared lifestyle risk factors for T2D and breast cancer, providing support for lifestyle modification as an 
effective prevention strategy to reduce the risk of both T2D and breast cancer. Our finding of significant 
associations of three T2D risk variants with breast cancer suggests a potential link of certain shared genetic 
and biological pathways for these common diseases. 
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FIGURE LEGENDS 
Fig. 1 Overview of the T2D genetic risk score construction 
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Supplemental Table 1 Studies participating in the Breast Cancer Association Consortium (BCAC) that contributed to this project 
Study (reference) Abbreviation Country Study design Recruitment base 
    Cases Controls 
Australian Breast 
Cancer Family Study 
[1] 
ABCFS Australia Population-based 
case-control study 
Cancer registries in Victoria and New 
South Wales (1992-1999): all cases from 
Melbourne and Sydney diagnosed 
before age 40 plus a random sample of 
those diagnosed at ages 40-59. 
Identified between 1992 and 1999 
from the electoral rolls in 
Melbourne and Sydney (enrolling to 
vote is compulsory); frequency 
matched to cases by age in 5-year 
categories. 
Amsterdam Breast 
Cancer Study [2] 
ABCS Netherlands Hospital-based 
consecutive 
cases; population-
based controls 
Breast cancer patients diagnosed before 
age 50 in 2003-2009 at the NKI-AVL; and 
(ABCS-F) All non-BRCA1/2 breast cancer 
cases from the family cancer clinic of 
the NKI-AVL tested in the period 1995-
2009; all ages and diagnosed with 
breast cancer in 1965-2008.    
Population-based cohort of women 
recruited through the Sanquin 
blood bank, all ages. 
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Bavarian Breast 
Cancer Cases and 
Controls [3] 
BBCC Germany Hospital based 
cases; population 
based controls 
Consecutive, unselected cases with 
invasive breast cancer recruited at the 
University Breast Centre, Franconia in 
Northern Bavaria from 2002-2010. 
Healthy women aged 55 or older 
with no diagnosis of cancer. Invited 
by a newspaper advertisement in 
Northern Bavaria from 2002-2010. 
British Breast Cancer 
Study [4] 
BBCS UK Cancer registry 
and National 
Cancer Research 
network (NCRN) 
based cases; 
population based 
controls 
 (i) English & Scottish Cancer Registries: 
all breast cancer cases who developed a 
first primary before age 66 in 1971 or 
later and who subsequently developed 
a second primary cancer. 
(ii) Breast Cancer Clinics: all breast 
cancer cases who developed a first 
primary before age 71 in 1967 or later 
and who either subsequently developed 
a second primary or had at least two 
affected female first-degree relatives. 
All recruited from 2001-2008. 
A friend, sister-in-law, daughter-in-
law or other non-blood relative of 
cases, recruited from 2001-2008. 
Breast Cancer in 
Galway Genetic Study 
[5] 
BIGGS Ireland Hospital based 
cases; population 
based controls 
Unselected cases recruited from 
University College Hospital Galway and 
surrounding hospitals in the West of 
Ireland since 2001. 
Women > 60 years with no personal 
history of any cancer and no family 
history of breast or ovarian cancer 
identified from retirement groups 
in the West of Ireland during 2001-
2008. 
Breast Cancer Study 
of the University of 
Heidelberg [6] 
BSUCH Germany Hospital based 
cases; healthy 
blood donor 
controls 
All cases diagnosed with breast cancer 
in 2007-2009 at the University Women`s 
Clinic Heidelberg.  
Female blood donors recruited in 
2007- 2009 at the Institute of 
Transfusion Medicine & 
Immunology, Mannheim.  
CECILE Breast Cancer 
Study [7] 
CECILE France Population-based 
case-control 
All cases diagnosed with breast cancer 
in 2005-2007 among women <75 years 
of age residing in the départements of 
Ille-et-Vilaine and Côte d'Or. Cases were 
recruited from the main cancer 
treatment center (Centre Eugène-
Marquis in Rennes and Centre Georges-
François-Leclerc in Dijon) and from 
other private or public hospitals in each 
area. 
General population control women 
residing in the same areas as the 
cases (Ille-et-Vilaine and Côte d’Or). 
Controls were frequency-matched 
to the cases by 5-year age groups. 
They were recruited in 2005-2007 
using a random digit dialing 
procedure and quotas by 
socioeconomic status to reflect the 
distribution by SES of the 
population in each area. 
Copenhagen General 
Population Study [8] 
CGPS Denmark Population-based Consecutive, incident cases from one 
hospital with centralized care for a 
population of 400,000 women in 
Copenhagen (2001-present). 
Women with no history of breast 
cancer residing in the same region 
as cases identified from the 
Copenhagen General Population 
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Study (2003-2007). 
Spanish National 
Cancer Centre Breast 
Cancer Study [9] 
CNIO-BCS Spain Case-control 
study 
(i) consecutive breast cancer patients 
from three public hospitals, two in 
Madrid and one in Oviedo;  
(ii) cases with at least one affected first 
degree relative recruited through the 
CNIO family cancer clinic in Madrid 
(2000-2005). 
Women attending the Menopause 
Research Centre, Madrid and 
female members of the College of 
Lawyers attending medical check-
up in Madrid between 2000 and 
2005, all free of breast cancer. 
California Teachers 
Study [10] 
CTS* USA Prospective 
cohort study: 
nested case-
control 
Nested case-control study conducted 
within a cohort of California teachers 
(113,590) who were under age 80 years 
at baseline, had no prior history of 
invasive or in situ breast cancer. Cases 
are women newly diagnosed with a 
histologically confirmed invasive 
primary adenocarcinoma of the breast 
at age 80 years or younger from 1998 to 
2008. 
Controls are a probability sample of 
at-risk cohort members, frequency 
matched to cases on age at 
baseline (5-year age groups), self-
reported race/ethnicity (white, 
African American, Latina, Asian, 
other), and broad geographic 
region within California Controls 
were selected without 
replacement, using an assigned 
reference date. 
ESTHER Breast 
Cancer Study [11] 
ESTHER Germany Population-based 
case-control study 
Breast cancer cases in all hospitals in 
the state of Saarland, from 2001-2003 
(ESTHER) and 1996-1998 (VERDI). 
Random sample of women 
undergoing a routine health check-
up in Saarland, in 2000-2002; 
frequency matched to cases by age 
in-5 year categories. 
German Consortium 
for Hereditary Breast 
& Ovarian Cancer 
[12] 
GC-HBOC Germany Population-based 
familial case-
control study 
Index patients from German breast 
cancer families; BRCA1/2 mutation free, 
collected 1996-2007 via Institute of 
Human Genetics, University Heidelberg 
& Department of Gynaecology & 
Obstetrics, Cologne & Department of 
Gynaecology and Obstetrics at the 
Ludwig-Maximilians-University, Munich; 
Germany. 
Healthy, unrelated, ethnically 
matched female blood donors 
recruited in 2004 & 2007 by 
German Red Cross Blood Service of 
Baden-Württemberg-Hessen, 
Institute of Transfusion Medicine & 
Immunology, Mannheim. 
Gene Environment 
Interaction and 
Breast Cancer in 
Germany [13] 
GENICA* Germany Population-based 
case-control study 
Incident breast cancer cases were 
enrolled at hospitals in the Greater 
Bonn area during 2000-2004. 
Random address sample selected in 
2001-2004 from 31 population 
registries in the greater Bonn area; 
frequency matched to cases on 
year of birth in 5-year categories. 
8 
 
Helsinki Breast 
Cancer Study [14] 
HEBCS Finland Hospital-based 
case-control study 
+ additional 
familial cases  
(i) Consecutive cases (883) from the 
Department of Oncology, Helsinki 
University Central Hospital 1997-8 and 
2000,  
(ii) Consecutive cases (986) from the 
Department of Surgery, Helsinki 
University Central Hospital 2001-2004, 
(iii) Familial breast cancer patients (536) 
from the Helsinki University Central 
Hospital, Departments of Oncology and 
Clinical Genetics (1995-). 
Healthy females from the same 
geographical region in Southern 
Finland in 2003. 
Hannover-Minsk 
Breast Cancer Study 
[15] 
HMBCS Belarus Hospital based 
cases; population 
based controls 
Cases from the Byelorussian Institute 
for Oncology and Medical Radiology 
Aleksandrov N.N. in Minsk or at one of 5 
regional oncology centers in Gomel, 
Mogilev, Grodno, Brest or Vitebsk 
(2002-2008). 
Women attending general medical 
examination at gynecology clinics in 
Gomel, Mogilev, Grodno, Brest or 
Vitebsk; women attending the 
Institute for Inherited Diseases in 
Minsk; female blood donors in 
Minsk; healthy relatives of cases 
(2002-2008). 
Karolinska Breast 
Cancer Study [16] 
KARBAC Sweden Population and 
hospital-based 
cases; 
geographically 
matched controls 
(i) Familial cases from Department of 
Clinical Genetics, Karolinska University 
Hospital, Stockholm.  
(ii)  Consecutive cases from Department 
of Oncology, Huddinge & Söder 
Hospital, Stockholm 1998-2000.  
Blood donors of mixed gender from 
same geographical region. Excess 
material was received from all 
blood donors over a 3 month 
period in 2004 (approximately 
3000) and DNA was extracted from 
a random sample of 1500. 
Kuopio Breast Cancer 
Project [17] 
KBCP Finland Population-based 
prospective 
clinical cohort 
Women seen at Kuopio University 
Hospital between 1990-1995 because of 
a breast lump, mammographic 
abnormality, or other breast symptom 
and who were found to have breast 
cancer. 
Selected from the National 
Population Register during 1990-
1995; age and long-term area-of-
residence matched to cases. 
 
Kathleen Cuningham 
Foundation 
Consortium for 
research into Familial 
Breast 
Cancer/Australian 
Ovarian Cancer Study 
[18] 
KConFab/AOCS Australia 
and New 
Zealand 
Clinic-based 
recruitment of 
familial breast 
cancer patients 
(cases);  
population-based 
case-control study 
of ovarian cancer 
(controls only) 
Index (youngest affected) cases from 
BRCA1- and BRCA2-mutation-negative 
multiple-case breast and breast-ovarian 
families recruited though family cancer 
clinics from across Australia and New 
Zealand from 1998-present. 
Identified from the electoral rolls 
from across Australia as part of the 
Australian Ovarian Cancer Study in 
2002-2006. 
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Leuven 
Multidisciplinary 
Breast Centre [19] 
LMBC Belgium Hospital-based 
case-control study 
All patients diagnosed with breast 
cancer and seen in the Multidisciplinary 
Breast Center in Leuven (Gashuisberg) 
since June 2007 plus retrospective 
collection of cases diagnosed since 
2000. 
Blood donors at Gasthuisberg 
Hospital (2007-2008). 
Mammary Carcinoma 
Risk Factor 
Investigation [20] 
MARIE Germany Population-based 
case-control study 
Incident cases diagnosed from 2001-
2005 in the study region Hamburg in 
Northern Germany, and from 2002-
2005 in the study region Rhein-Neckar-
Karlsruhe in Southern Germany. 
Two controls per case were 
randomly drawn from population 
registries and frequency matched 
by birth year and study region to 
the case. Controls were recruited 
from 2002 to 2006. 
Milan Breast Cancer 
Study Group [21] 
MBCSG Italy Clinic-based 
recruitment of 
familial/early 
onset breast 
cancer patients 
(cases); 
population-based 
controls 
Familial and/or early onset breast 
cancer patients (aged 22-87) negative 
for mutations in BRCA1 and BRCA2, 
ascertained at two large cancer centers 
in Milan from 2000-present. 
Female blood donors recruited at 
two centres in Milan from 2004-
present and 2007-present. 
 
Mayo Clinic Breast 
Cancer Study [22] 
MCBCS USA Hospital-based 
case-control study 
Incident cases residing in 6 states (MN, 
WI, IA, IL, ND, SD) seen at the Mayo 
Clinic in Rochester, MN from 2002-
2010. 
Women presenting for general 
medical examination at the Mayo 
Clinic from 2002-2010; frequency 
matched to cases on age, ethnicity 
and county/state. 
Melbourne 
Collaborative Cohort 
Study [23] 
MCCS Australia Population-based 
prospective 
cohort study 
Incident cases from the cohort of 
24,469 women, diagnosed during the 
follow-up from baseline (1990-1994) to 
2008. 
Random sample of the initial 
cohort. 
Multi-ethnic Cohort 
[24] 
MEC USA Prospective 
cohort study: 
nested case-
control 
Incident cases identified from SEER 
cancer registries in Los Angeles County 
& State registries in California & Hawaii, 
USA from 1993-2002.  Grouped by self-
reported ethnicity. 
Women without cancer from the 
same States, recruited concurrently 
with cases & frequency matched to 
cases by age at blood-draw & self-
reported ethnicity. 
Montreal Gene-
Environment Breast 
Cancer Study [25] 
MTLGEBCS  Canada Population-based 
case-control study 
design 
All cases are postmenopausal women 
(47-75 years) living in Montreal with a 
primary invasive breast cancer and with 
no previous occurrence of any type of 
cancer. All cases were identified from 
2007 to 2010 in 15 of 16 Montreal 
hospitals that treat breast cancer.  
Random sample from the universal 
Provincial Voter Registration List, 
approximately frequency-matched 
to cases on age (5-year bins) and 
living in Montreal. 
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Norwegian Breast 
Cancer Study [26] 
NBCS* Norway Hospital-based 
case-control study 
Incidence cases from three different 
hospitals: Ullevål Univ. Hospital 1990-
94, Norwegian Radium Hospital 1975-
1986 and 1995-1998, Haukeland 
University Hospital 1992-2001. 
Women residing in Tromsø and 
Bergen who attended the 
Norwegian Breast Cancer Screening 
Program. 
Oulu Breast Cancer 
Study [27] 
OBCS Finland Hospital-based 
case-control study 
Consecutive incident cases diagnosed at 
the Oulu University Hospital during 
2000-2004. 
Female blood donors recruited in 
2002 from the same geographical 
region in Northern Finland. 
Ontario Familial 
Breast Cancer 
Registry [28] 
OFBCR Canada Population-based 
familial case-
control study  
Invasive cases aged 20-54 and a random 
sample aged 55-69 years identified from 
the Ontario Cancer Registry from 1996-
1998. All those at high genetic risk were 
eligible; random samples of women not 
meeting these criteria were also asked 
to participate. During 2001-2005, 
enrollment was limited to minority and 
high-risk families. 
Identified by calling randomly 
selected residential telephone 
numbers in the same geographical 
region from 1998-2001; frequency 
matched to cases by age in 5 year 
categories. 
Leiden University 
Medical Centre 
Breast Cancer Study 
[29] 
ORIGO Netherlands Hospital-based 
prospective 
cohort study 
Consecutive case patients diagnosed 
1996-2006 in 2 hospitals in South-West 
Netherlands (Leiden & Rotterdam). No 
selection for family history; Rotterdam 
case patients selected for diagnosis 
aged <70. Case patients with in situ 
carcinomas eligible. 
 (1) Blood bank healthy donors 
from Southwest Netherlands 
recruited in 1996, 2000 or 2007; (2) 
People who married a person who 
was part of a family with high 
breast cancer risk (BRCA1/2/X). 
From the Southwest of the 
Netherlands, recruited 1990-1996; 
(3) Females tested at the local 
clinical genetics department for 
familial diseases, excluding familial 
cancer syndromes (no mutation 
found in gene(s) related to the 
disease being tested), recruited 
1995-2007. 
NCI Polish Breast 
Cancer Study [30] 
PBCS Poland Population-based 
case-control study 
Incident cases identified through a rapid 
identification system in participating 
hospitals covering ~ 90% of all eligible 
cases, and cancer registries in Warsaw 
and Łódź covering 100% of all eligible 
cases (2000-2003). 
Randomly selected from population 
lists of all residents of Poland from 
2000-2003, stratified and frequency 
matched to cases on city and age in 
5-year categories. 
Karolinska 
Mammography 
Project for Risk 
pKARMA Sweden Case-control 
study 
Incident cases from Jan 2001 - Dec 2008 
from the Stockholm/Gotland area. 
Identified through the Stockholm breast 
Unmatched participants of the 
KARMA mammography screening 
study recruited between 2010 and 
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Prediction of Breast 
Cancer - prevalent 
cases [25] 
cancer registry. 2011 from Southern Sweden and 
Stockholm. 
Rotterdam Breast 
Cancer Study [31] 
RBCS Netherlands Hospital based 
case-control 
study, Rotterdam 
area 
Familial breast cancer patients selected 
from the clinical genetics center at 
Erasmus Medical Center during 1994-
2005. 
Spouses or mutation-negative 
siblings of heterozygous Cystic 
Fibrosis mutation carriers selected 
from the clinical genetics center at 
Erasmus Medical Center during 
1996-2006. 
Singapore and 
Sweden Breast 
Cancer Study [32] 
SASBAC Sweden Population-based 
case-control study 
Women diagnosed in Sweden aged 50-
74 in 1993-1995. 
Population-based controls 
frequency matched by age to the 
cases. 
Sheffield Breast 
Cancer Study [33] 
SBCS UK Hospital-based 
case-control study  
Women with breast cancer recruited in 
1998-2005 at surgical outpatient clinics 
at the Royal Hallamshire Hospital, 
Sheffield. 
Unselected women attending the 
Sheffield Mammography Screening 
Service in 2000-2004 with no 
evidence of a breast lesion.  
Study of 
Epidemiology and 
Risk factors in Cancer 
Heredity [34] 
SEARCH UK Population-based 
case-control study 
Identified through the Eastern Cancer 
Registration and Information 
Centre: (i) prevalent cases; 
diagnosed 1991-1996; under 55 years of 
age at diagnosis; recruited 1996-2002  
(ii) incident cases; diagnosed since 1996; 
under 70 years of age at diagnosis; 
recruited 1996-present. 
(a) Women from the same 
geographic region selected from 
the EPIC-Norfolk cohort study, 
1992-1994 (b) women attending GP 
practices, frequency matched to 
cases by age and geographic region 
(2003-2010) (c) women attending 
for breast screening as part of the 
NHSBSP participating in the Sisters 
in Breast Screening (SIBS) study 
Städtisches Klinikum 
Karlsruhe Deutsches 
Krebsforschungszentr
um Study [35] 
SKKDKFZS* Germany Hospital-based 
breast cancer 
cohort 
Women diagnosed with primary in situ 
or invasive breast cancer at the 
Städtisches Klinikum Karlsruhe from 
March 1993 to July 2005. Cases were 
21-93 years of age. 
Controls for triple negative cases 
were from an unselected series of 
unaffected women from the same 
geographical region. 
IHCC-Szczecin Breast 
Cancer Study [36] 
SZBCS Poland Hospital based 
case-control study 
Prospectively ascertained cases of 
invasive breast cancer patients 
diagnosed at the Regional Oncology 
Hospital (2002-2003 and 2006-2007) or 
the University Hospital (2002-2007), 
both in Szczecin, West Pomerania, 
Poland.  
Selected from a population-based 
study of the 1.3 million inhabitants 
of West Pomerania (2003-2004); 
matched to cases for year of birth, 
sex and region. 
 
Triple Negative 
Breast Cancer 
Consortium Study 
TNBCC* Multiple Multiple Triple negative invasive breast cancer 
cases from multiple countries 
Women free of breast cancer from 
the same geographic regions as 
cases 
12 
 
[37] 
UK Breakthrough 
Generations Study 
[38] 
 
UKBGS UK Prospective 
cohort study: 
nested case-
control study of 
women who had 
not had breast 
cancer prior to 
entry into the 
cohort 
Cohort members who developed breast 
cancer or in situ breast cancer after 
entry into the Breakthrough 
Generations Study (cohort of 
>100,000 women followed up for breast 
cancer, recruited from the UK during 
2003-2010). 
Women who had not had breast 
cancer or in situ breast cancer 
selected by 1:1 matching to cases 
on date of birth, year of entry in to 
the study (2003-2010),  source of 
recruitment, availability of blood 
sample and ethnicity. 
*CTS, NBCS and SKKDKFZ are studies in BCAC but were genotyped as part of the triple negative consortium (TNBCC). Part of GENICA was also genotyped as part of TNBCC. Samples 
in all studies included in our analysis were unique. 
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Supplemental Table 2 Breast Cancer GWAS included in the GAME-ON DRIVE Meta-analysis 
Study Country Case Ascertainment Control Ascertainment Genotyping platform Cases Controls 
ABCFS/kConFab [1] Australia Recruitment through cancer 
registries in Victoria and 
New South Wales 
Recruitment from the 
electoral rolls in Melbourne 
and Sydney matched to 
cases by age in 5-year 
categories 
Illumina 610k 282 285 
BBCS [4] UK Recruitment through cancer 
registries and clinics in the 
UK, predominantly bilateral 
cases 
WTCCC2: 1958 Birth Cohort 
+ UK National Blood Service 
Illumina 370k (cases) 
Illumina 1.2M 
(controls) 
1609 5190 
GC-HBOC [12] Germany BRCA1/2 mutation negative 
cases from University 
Clinics in Cologne and 
Munich 
KORA (Cooperative Health 
Research in the Region 
Augsburg) 
Affymetrix 5.0k (cases) 
Affymetrix 6.0k 
(controls) 
634 477 
MARIE [20] Germany Random sample of cases 
from the MARIE study, but 
restricted to ductal and 
lobular carcinomas and 
oversampled for lobular 
(about 2:1) 
KORA (Cooperative Health 
Research in the Region 
Augsburg) 
Illumina 370k (cases) 
Illumina 550k 
(controls) 
708 470 
HEBCS [14,39] Finland Unselected cases plus 
additional familial cases 
from Helsinki University 
Central Hospital 
Population Controls from 
from the NordicDB, a 
Nordic pool and portal for 
genome-wide control data 
llumina 550k + 610k 
(cases) Illumina 370k 
(controls) 
810 1012 
SASBAC [14] Sweden Population- based case 
control study of 
postmenopausal women 
Population-based controls 
frequency matched by age 
to cases 
Illumina 317k+240k 
(cases) Illumina 550k 
(controls) 
790 756 
UK2 [40] UK UK cancer genetics clinics + 
oncology clinics 
WTCCC2: 1958 Birth Cohort 
+ UK National Blood Service 
Illumina 670k (cases) 
Illumina 1.2M 
(controls) 
3628 5190 
14 
 
DFBBCS [41] Netherlands BRCA1/2 mutation negative 
familial bilateral breast 
cancer patients selected 
from five clinical genetics 
centers; Erasmus University 
Medical Center/Daniel den 
Hoed, The Netherlands 
Cancer Institute, Leiden 
University Medical Center, 
University Medical Center 
Utrecht, and VU University 
Medical Center. 
Controls were from the 
Rotterdam study, and are 
55 years or older at the 
time of inclusion. For this 
study females were 
selected and breast cancer 
cases were excluded. 
Illumina 610k (cases) 
Illumina 550k 
(controls) 
464 3265 
BPC3 [42] US/Europe Estrogen Receptor negative 
cases from population 
based cohorts within the 
Breast and Prostate cancer 
cohort consortium (BPC3) 
Individually matched within 
cohorts in BPC3 
Illumina 
660k+550K+317k 
2188 25519 
Early-onset Breast 
Cancer GWAS [43] 
US/Europe/Australia Population-based subjects 
were recruited from eight 
sites, some of which 
oversampled cases with a 
personal or family history. 
Eligible cases were non-
Hispanic White women 
diagnosed with invasive 
breast cancer when 51 
years or younger and not 
known to carry pathogenic 
mutations in BRCA1 or 
BRCA2. 
Eligible controls were non-
hispanic white women 
aged 20-51 years without a 
history of breast cancer, 
who were identified largely 
by random-digit dialing. 
Illumina 610k + Cyto 
12) 
3523 2702 
SardiNIA (N/A) Italy  N/A  N/A Affymetrix 500k 
(cases) Affymetrix 6.0k 
(controls) 
1367 1659 
GAME-ON=Genetic Associations and Mechanisms in Oncology. DRIVE=Discovery, Biology, and Risk of Inherited Variants in Breast Cancer. N/A=no data were available. 
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Supplemental Table 3 Associations of the 33 T2D related SNPs with breast cancer risk in the BCAC, GAME-ON DRIVE, and combined.  
   
 
    
BCAC 
(Cases N=46325/ Controls N=42482)  
GAME-ON DRIVE 
(Cases N=16003/ Controls N=41335)  
Combined 
(Cases N=62328/ Controls 
N=83817) 
SNPs Chr Positiona Region Geneb Allelesc R2 d 
 
RAFe ORf 95% CIf Pf 
 
RAF OR 95% CI P 
 
OR 95% CI P 
rs10923931 1 120517959 1p12 
NOTCH2,  
ADAM30 T/G - 
 
0.11 1.02 (0.99,1.06) 0.17 
 
0.11 1.03 (0.98,1.09) 0.292 
 
1.02 (1.00,1.05) 0.09 
rs7578597 2 43732823 2p21 THADA T/C 0.998 
 
0.9 1.00 (0.97,1.03) 0.92 
 
0.89 0.99 (0.94,1.05) 0.744 
 
1.00 (0.97,1.02) 0.80 
rs243021 2 60584819 2p16.1 BCL11A A/G - 
 
0.46 1.02 (1.00,1.04) 0.03 
 
0.46 1.01 (0.98,1.05) 0.448 
 
1.02 (1.00,1.04) 0.02 
rs7593730 2 161171454 2q24.2 
RBMS1, 
 ITGB6 C/T 0.994 
 
0.79 0.99 (0.97,1.01) 0.44 
 
0.77 1.01 (0.97,1.05) 0.66 
 
1.00 (0.97,1.02) 0.66 
rs2943641 2 227093745 2q36.3 
LOC64673, 
 IRS1 C/T - 
 
0.64 1.00 (0.98,1.02) 0.72 
 
0.65 1.02 (0.98,1.05) 0.347 
 
1.01 (0.99,1.03) 0.43 
rs4607103 3 64711904 3p14.1 ADAMTS9 C/T 0.947 
 
0.75 0.99 (0.97,1.02) 0.60 
 
0.77 1.02 (0.98,1.06) 0.377 
 
1.00 (0.98,1.02) 1.00 
rs4402960 3 185511687 3q27.2 IGF2BP2 T/G - 
 
0.31 0.98 (0.96,1.00) 0.05 
 
0.32 0.97 (0.94,1.01) 0.129 
 
0.98 (0.96,1.00) 0.01 
rs4689388 4 6270056 4p16.1 
WFS1,  
PPP2R2C A/G - 
 
0.58 1.00 (0.98,1.02) 0.96 
 
0.58 1.01 (0.98,1.05) 0.584 
 
1.00 (0.99,1.02) 0.75 
rs4457053 5 76424949 5q13.3 ZBED3 G/A 0.855 
 
0.29 0.99 (0.97,1.02) 0.66 
 
0.32 1.00 (0.96,1.04) 0.971 
 
1.00 (0.98,1.02) 0.71 
rs10440833 6 20688121 6p22.3 CDKAL1 A/T 0.984 
 
0.27 1.01 (0.99,1.03) 0.42 
 
0.27 1.05 (1.02,1.1) 0.006 
 
1.02 (1.00,1.04) 0.04 
rs864745 7 28180556 7p15.1 JAZF1 T/C 0.997 
 
0.5 0.98 (0.96,1.00) 0.08 
 
0.49 0.95 (0.92,0.98) 0.004 
 
0.97 (0.96,0.99) 3.11E-03 
rs972283 7 130466854 7q32.3 KLF14 G/A 0.546 
 
0.54 1.01 (0.98,1.04) 0.51 
 
0.51 1.01 (0.97,1.05) 0.704 
 
1.01 (0.99,1.03) 0.45 
rs896854 8 95960511 8q22.1 TP53INP1 T/C 0.953 
 
0.52 1.00 (0.98,1.02) 0.90 
 
0.48 1.01 (0.97,1.04) 0.662 
 
1.00 (0.99,1.02) 0.74 
rs3802177 8 118185025 8q24.11 SLC30A8 G/A 0.997 
 
0.69 1.01 (0.99,1.03) 0.56 
 
0.69 1.01 (0.98,1.05) 0.438 
 
1.01 (0.99,1.03) 0.37 
rs10811661 9 22134094 9p21.3 
CDKN2A, 
CDKN2B T/C - 
 
0.83 0.98 (0.96,1.01) 0.21 
 
0.81 0.96 (0.92,1.01) 0.108 
 
0.98 (0.96,1.00) 0.06 
rs7018475 9 22137685 9p21.3 CDKN2B T/G - 
 
0.74 1.00 (0.97,1.02) 0.71 
 
- - - - 
 
1.00 (0.97,1.02) 0.71 
rs13292136 9 81952128 9q21.31 CHCHD9 C/T 0.926 
 
0.92 1.05 (1.01,1.09) 0.02 
 
0.94 0.98 (0.92,1.05) 0.621 
 
1.03 (1.00,1.07) 0.08 
rs12779790 10 12328010 10p13 
CDC123, 
CAMK1D G/A 0.697 
 
0.18 1.00 (0.97,1.03) 0.93 
 
0.19 0.99 (0.94,1.03) 0.597 
 
1.00 (0.97,1.02) 0.83 
rs5015480 10 94465559 10q23.33 HHEX,IDE C/T 0.979 
 
0.58 0.99 (0.97,1.01) 0.36 
 
0.59 1.00 (0.96,1.03) 0.794 
 
0.99 (0.97,1.01) 0.35 
rs7903146 10 114758349 10q25.2 TCF7L2 T/C - 
 
0.28 1.04 (1.02,1.07) 1.20E-04 
 
0.3 1.04 (1.00,1.08) 0.038 
 
1.04 (1.02,1.06) 1.26E-05 
rs231362 11 2691471 11p15.5 KCNQ1 G/A 0.705 
 
0.52 1.01 (0.99,1.04) 0.22 
 
0.5 1.00 (0.97,1.04) 0.815 
 
1.01 (0.99,1.03) 0.25 
rs5215 11 17408630 11p15.1 KCNJ11 C/T - 
 
0.38 0.99 (0.97,1.01) 0.17 
 
0.36 0.99 (0.96,1.03) 0.599 
 
0.99 (0.97,1.00) 0.15 
rs1552224 11 72433098 11q13.4 CENTD2 A/C 0.859 
 
0.83 0.99 (0.96,1.01) 0.34 
 
0.84 1.01 (0.96,1.06) 0.667 
 
0.99 (0.97,1.02) 0.55 
rs1387153 11 92673828 11q14.3 MTNR1B T/C 0.581 
 
0.28 1.02 (0.99,1.05) 0.22 
 
0.3 0.98 (0.94,1.02) 0.375 
 
1.01 (0.98,1.03) 0.63 
rs1531343 12 66174894 12q14.3 HMGA2 C/G 0.943 
 
0.09 1.02 (0.99,1.06) 0.23 
 
0.1 1.01 (0.95,1.07) 0.782 
 
1.02 (0.99,1.05) 0.25 
rs7961581 12 71663102 12q21.1 
TSPAN8, 
LGR5 C/T 0.981 
 
0.28 0.97 (0.94,0.99) 2.48E-03 
 
0.26 1.00 (0.96,1.04) 0.962 
 
0.97 (0.96,0.99) 9.01E-03 
16 
 
rs7957197 12 121460686 12q24.31 HNF1A T/A 0.981 
 
0.8 1.00 (0.98,1.03) 0.72 
 
0.81 1.03 (0.98,1.07) 0.21 
 
1.01 (0.99,1.03) 0.35 
rs7178572 15 77747190 15q24.3 HMG20A G/A - 
 
0.71 1.02 (0.99,1.04) 0.14 
 
0.71 1.04 (1.00,1.08) 0.048 
 
1.02 (1.00,1.04) 0.02 
rs11634397 15 80432222 15q25.1 ZFAND6 G/A 0.938 
 
0.65 1.01 (0.99,1.04) 0.21 
 
0.66 1.04 (1.00,1.09) 0.035 
 
1.02 (1.00,1.04) 0.04 
rs8042680 15 91521337 15q26.1 PRC1 A/C - 
 
0.31 0.98 (0.95,1.00) 0.02 
 
0.3 0.95 (0.92,0.99) 0.006 
 
0.97 (0.95,0.99) 8.05E-04 
rs9939609 16 53820527 16q12.2 FTO A/T 1.000 
 
0.4 0.93 (0.91,0.95) 3.63E-12 
 
0.38 0.96 (0.93,0.99) 0.013 
 
0.94 (0.92,0.95) 4.13E-13 
rs8090011 18 7068462 18p11.31 LAMA1 G/C 0.864 
 
0.39 1.00 (0.98,1.02) 0.80 
 
0.38 1.03 (0.99,1.07) 0.111 
 
1.01 (0.99,1.03) 0.30 
rs5945326 23 152899922 Xq28 DUSP9 A/G 0.698   0.79 1.00 (0.97,1.02) 0.84   0.77 0.98 (0.92,1.03) 0.391   0.99 (0.97,1.02) 0.58 
SNP: single nucleotide polymorphism; Chr: Chromosome; BCAC: Breast Cancer Association Consortium; GAME-ON: Genetic Associations and Mechanisms in Oncology; DRIVE: Discovery, Biology, and Risk of Inherited Variants in 
Breast Cancer; RAF: risk allele frequency; OR: odds ratio; CI: confidence interval;  
a: The chromosome physical position is based on the National Center for Biotechnology Information (NCBI) database, Build 36.3.  
b: The closest gene.  
c: Alleles risk/reference alleles. Risk allele associated with increased risk of type 2 diabetes. 
d: Imputation quality in BCAC; - indicates directly genotyped SNPs. 
e: Among controls. 
f: All associations were assessed individually by study and then combined by a fixed-effects inverse-variance weighted meta-analysis.  All models adjusted for top eight principal components for population stratification. Study 
specific principal component was further adjusted for LMBC study. 
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Supplemental Table 4 Subject characteristics by case-control status and their associations with weighted type 2 
diabetes genetic risk score in Breast Cancer Association Consortium 
 
 Breast cancer 
 
T2D GRSe 
 
 Casea Controla 
P-Valueb 
 
Association/ 
Summaryc 
P-Valued 
Breast cancer risk factors N (N=46325) (N=42482) 
 Age (years) 80455 57.8 ± 11.2 54.9 ± 11.9 <0.01 
 
0.006 0.26 
Age at menarche (years) 53990 13.1 ± 1.6 13.1 ± 1.6 0.30 
 
-0.021 <0.01 
Age at menopause (years) 26921 48.5 ± 5.8 48.7 ± 5.9 <0.01 
 
-0.004 0.71 
Age at first live birth (years) 44735 25.1 ± 4.9 25.4 ± 4.8 <0.01 
 
-0.014 0.05 
Body mass index
f
 (kg/m
b
)  31514 26.4 ± 4.9 26.4 ± 4.8 0.62 
 
0.018 0.03 
Parity (numbers) 61837  1.9 ± 1.3  2.0 ± 1.3 <0.01 
 
-0.0005 0.93 
Family history of breast cancer 47417 
  
<0.01 
  
0.12 
    No  21425 (72.3) 15781 (88.8) 
  
4.60 ± 0.52 
     Yes  8221 (27.7) 1990 (11.2) 
  
4.62 ± 0.52 
 Menopausal status 61686 
  
<0.01 
  
0.69 
    Pre  10209 (30.7) 9053 (31.9) 
  
4.58 ± 0.52 
     Post  23069 (69.3) 19355 (68.1) 
  
4.58 ± 0.51 
 Parous 62683 
  
<0.01 
  
0.74 
    Nulliparous  5205 (15.7) 4305 (14.6) 
  
4.58 ± 0.52 
     Parous  27986 (84.3) 25187 (85.4) 
  
4.58 ± 0.52 
 Breastfeeding
g
 34778 
  
<0.01 
  
<0.01 
    Never  3409 (17.0)    2731 (18.5)   
  
4.62 ± 0.51 
     Ever  16632 (83.0)    12006 (81.5) 
  
4.56 ± 0.52 
 Use of oral contraceptives 28941 
  
<0.01 
  
0.91 
    Never  6553 (39.9) 4297 (34.3) 
  
4.58 ± 0.52 
     Ever  9852 (60.1) 8239 (65.7) 
  
4.58 ± 0.52 
 Use of hormone replacement 
therapy 30983 
  
0.87 
  
0.32 
    Never  10463 (61.0) 8429 (60.9) 
  
4.58 ± 0.51 
     Ever  6685 (39.0) 5406 (39.1) 
  
4.58 ± 0.52 
 Smoking status 39562 
  
<0.01 
  
0.21 
    Never  10104 (50.1) 10386 (53.5) 
  
4.57 ± 0.52 
     Past  6331 (31.4) 6529 (33.6) 
  
4.58 ± 0.52 
     Current  3719 (18.5) 2493 (12.8)     4.55 ± 0.51   
T2D GRS: Weighted type 2 diabetes related genetic variants risk score 
a
: Mean±sd for continuous variables and frequency (percentage) for categorical variables 
b
: Wilcoxon’s test for continuous variables and Pearson’s test for categorical variables
  
c
: For continuous variables, Pearson’s correlations(r) between each risk factor and T2D GRS are presented; For categorical 
variables, T2D GRS summary statistics (mean±sd) by risk factor categories are presented 
d
: Test for correlation for continuous variables, and Wilcoxon’s test for categorical variables. 
e
: Among breast cancer controls
 
f
: Among postmenopausal women 
g
: Among parous women 
18 
 
 
Supplemental Table 5 Sensitivity analysis of the associations between T2D GRS and breast cancer risk in Breast Cancer 
Association Consortium using genotyped SNPs and imputed SNPs with a R2 > 0.9. 
 T2D GRS by Quintiles  
 Q1 (low) Q2 Q3 Q4 Q5 Linear Trend 
Overall Breast Cancer 
    Ncases/Ncontrols  9196/8497 9459/8496 9209/8496 9326/8496 9135/8497  
    OR
a
 [95% CI] 1 (reference) 1.02 (0.98,1.07) 1.00 (0.95,1.04) 1.01 (0.96,1.05) 0.99 (0.95,1.03)  
    P-Value
a
  0.3 0.83 0.69 0.64 0.45 
 
ER+ Breast Cancer 
    Ncases/Ncontrols  5439/8497 5544/8496 5368/8496 5397/8496 5326/8497  
    OR
a
 [95% CI] 1 (reference) 1.02 (0.97,1.08) 0.99 (0.94,1.05) 1.01 (0.96,1.07) 0.99 (0.94,1.04)  
    P-Value
a
  0.37 0.83 0.59 0.72 0.61 
 
ER- Breast Cancer 
    Ncases/Ncontrols  1407/8497 1501/8496 1437/8496 1493/8496 1450/8497  
    OR
a
 [95% CI] 1 (reference) 1.05 (0.96,1.14) 0.98 (0.90,1.07) 1.01 (0.93,1.10) 0.97 (0.89,1.06)  
    P-Value
a
  0.31 0.68 0.82 0.49 0.38 
 
Among Pre-menopausal Women 
    Ncases/Ncontrols  2022/1824 2119/1849 1972/1770 2032/1815 2064/1795  
    OR
a
 [95% CI] 1 (reference) 1.06 (0.96,1.18) 1.00 (0.90,1.12) 1.00 (0.90,1.11) 1.06 (0.95,1.18)  
    P-Value
a
  0.25 0.94 0.97 0.29 0.71 
 
Among Post-menopausal Women 
    Ncases/Ncontrols  4702/3887 4751/3903 4604/3863 4553/3852 4459/3850  
    OR
a
 [95% CI] 1 (reference) 1.02 (0.95,1.09) 1.00 (0.94,1.07) 1.00 (0.93,1.07) 0.99 (0.92,1.06)  
    P-Value
a
  0.61 0.99 0.94 0.73 0.6 
 
Among Age<50 Women 
   Ncases/Ncontrols 1823/2365 1919/2387 1852/2388 1890/2364 1902/2388  
    OR
a
 [95% CI] 1 (reference) 1.05 (0.95,1.16) 0.99 (0.89,1.10) 1.01 (0.91,1.12) 1.02 (0.92,1.13)  
    P-Value
a
  0.34 0.84 0.85 0.68 0.94 
 
Among Age≥50 Women 
    Ncases/Ncontrols  7373/6132 7540/6109 7357/6108 7436/6132 7233/6109  
    OR
a
 [95% CI] 1 (reference) 1.02 (0.97,1.07) 1.00 (0.95,1.06) 1.01 (0.96,1.06) 0.98 (0.93,1.03)  
    P-Value
a
  0.47 0.93 0.78 0.46 0.37 
 
Among BMI<25 Women 
    Ncases/Ncontrols  2431/2189 2546/2103 2348/2136 2391/2160 2454/2166  
    OR
a
 [95% CI] 1 (reference) 1.07 (0.98,1.18) 0.98 (0.89,1.07) 0.97 (0.88,1.06) 1.05 (0.96,1.15)  
    P-Value
a
  0.12 0.67 0.49 0.27 0.94 
 
Among BMI≥25 Women 
    Ncases/Ncontrols 2517/2156 2589/2280 2603/2294 2605/2263 2651/2339  
    OR
a
 [95% CI] 1 (reference) 0.99 (0.91,1.08) 0.96 (0.88,1.05) 1.00 (0.91,1.09) 0.96 (0.88,1.05)  
    P-Value
a
  0.82 0.42 0.95 0.34 0.43 
T2D GRS: Weighted type 2 diabetes related genetic variants risk score 
a
: All associations were assessed individually by each study and then combined by fixed-effect inverse-variance weighted meta-analysis. All 
models adjusted for age and top eight principal components for population stratification. Study specific principal component was further 
adjusted for LMBC study. 
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Supplemental Table 6 Validation of the developed T2D GRS with prior history of diabetes among controls from the 
Nashville Breast Health Study, 2001-2011[44] 
 T2D GRS by Quintiles  
History of diabetes Q1 (low) Q2 Q3 Q4 Q5 Linear Trend 
 
 
    Yes/No 13/277 19/272 17/272 24/267 35/254  
    OR
a
 [95% CI] 1 
(reference
) 
1.58 (0.76,3.28) 1.38 (0.65,2.92) 2.08 (1.02,4.21) 2.95 (1.51,5.75) <0.01 
       
T2D GRS: Weighted type 2 diabetes related genetic variants risk score 
a
: All models adjusted for age and top four principal components.  
 
 
 
Supplemental References 
 1. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL (2003) Familial 
risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95 (6):448-457 
2. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ 
(2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC 
germline mutation. J Clin Oncol 25 (1):64-69. doi:10.1200/JCO.2006.06.3024 
3. Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, 
Strick R, Beckmann MW, Fasching PA (2008) Single nucleotide polymorphism D1853N of the ATM gene may alter the risk 
for breast cancer. J Cancer Res Clin Oncol 134 (8):873-882. doi:10.1007/s00432-008-0355-9 
4. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, Ashworth A, Peto J (2006) Inconsistent 
association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 98 (14):1014-1018. 
doi:10.1093/jnci/djj268 
5. Colleran G, McInerney N, Rowan A, Barclay E, Jones AM, Curran C, Miller N, Kerin M, Tomlinson I, Sawyer E (2010) The 
TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat 119 
(2):437-442. doi:10.1007/s10549-009-0395-0 
6. Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, 
Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Muller H, Arndt V, Brenner H, Sohn 
C, Burwinkel B (2011) Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast 
Cancer Res Treat 127 (2):549-554. doi:10.1007/s10549-010-1244-x 
7. Villeneuve S, Fevotte J, Anger A, Truong T, Lamkarkach F, Gaye O, Kerbrat P, Arveux P, Miglianico L, Imbernon E, 
Guenel P (2011) Breast cancer risk by occupation and industry: analysis of the CECILE study, a population-based case-
control study in France. Am J Ind Med 54 (7):499-509. doi:10.1002/ajim.20952 
8. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG (2007) Increased risk of breast cancer 
associated with CHEK2*1100delC. J Clin Oncol 25 (1):57-63. doi:10.1200/JCO.2005.05.5160 
9. Milne RL, Ribas G, Gonzalez-Neira A, Fagerholm R, Salas A, Gonzalez E, Dopazo J, Nevanlinna H, Robledo M, Benitez J 
(2006) ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. 
Cancer Res 66 (19):9420-9427. doi:10.1158/0008-5472.CAN-06-1418 
10. Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West 
D, Wright W, Ziogas A, Ross RK (2002) High breast cancer incidence rates among California teachers: results from the 
California Teachers Study (United States). Cancer Causes Control 13 (7):625-635 
20 
 
 
11. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H 
(2008) Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 3 
(7):e2656. doi:10.1371/journal.pone.0002656 
12. Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, Schmutzler RK, Bugert P, Untch M, Bartram CR, 
Burwinkel B (2006) Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with 
the CASP8 D302H variant. Carcinogenesis 27 (3):606-609. doi:10.1093/carcin/bgi248 
13. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Bruning T, Vollmert C, Illig T, 
Dippon J, Ko YD, Brauch H (2008) The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast 
cancer. Breast Cancer Res Treat 111 (1):171-177. doi:10.1007/s10549-007-9762-x 
14. Li J, Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Martens 
JW, van den Ouweland AM, Alfredsson L, Palotie A, Peltonen-Palotie L, Irwanto A, Low HQ, Teoh GH, Thalamuthu A, 
Easton DF, Nevanlinna H, Liu J, Czene K, Hall P (2011) A combined analysis of genome-wide association studies in breast 
cancer. Breast Cancer Res Treat 126 (3):717-727. doi:10.1007/s10549-010-1172-9 
15. Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dork T (2010) High frequency and allele-
specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 
78 (4):364-372. doi:10.1111/j.1399-0004.2010.01473.x 
16. Margolin S, Werelius B, Fornander T, Lindblom A (2004) BRCA1 mutations in a population-based study of breast 
cancer in Stockholm County. Genet Test 8 (2):127-132. doi:10.1089/1090657041797365 
17. Hartikainen JM, Tuhkanen H, Kataja V, Dunning AM, Antoniou A, Smith P, Arffman A, Pirskanen M, Easton DF, 
Eskelinen M, Uusitupa M, Kosma VM, Mannermaa A (2005) An autosome-wide scan for linkage disequilibrium-based 
association in sporadic breast cancer cases in eastern Finland: three candidate regions found. Cancer Epidemiol 
Biomarkers Prev 14 (1):75-80 
18. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, McGuire V, Whittemore AS, 
Gayther SA, Pharoah PD, Webb PM, Chenevix-Trench G, Australian Ovarian Cancer Study G, Australian Cancer S, 
Australian Breast Cancer Family S (2007) Association between single-nucleotide polymorphisms in hormone metabolism 
and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. 
Cancer Epidemiol Biomarkers Prev 16 (12):2557-2565. doi:10.1158/1055-9965.EPI-07-0542 
19. De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, 
Christiaens MR, Vergote I, Leunen K, Amant F, Neven P (2008) Does estrogen receptor negative/progesterone receptor 
positive breast carcinoma exist? J Clin Oncol 26 (2):335-336; author reply 336-338. doi:10.1200/JCO.2007.14.8411 
20. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger 
J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of 
menopausal hormone therapy. Int J Cancer 123 (4):933-941. doi:10.1002/ijc.23655 
21. Catucci I, Verderio P, Pizzamiglio S, Manoukian S, Peissel B, Barile M, Tizzoni L, Bernard L, Ravagnani F, Galastri L, 
Pierotti MA, Radice P, Peterlongo P (2009) SNPs in ultraconserved elements and familial breast cancer risk. 
Carcinogenesis 30 (3):544-545; author reply 546. doi:10.1093/carcin/bgn289 
22. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, 
Vachon CM, Sellers TA, Weinshilboum RM (2007) A comprehensive examination of CYP19 variation and risk of breast 
cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 102 (2):237-247. doi:10.1007/s10549-006-
9324-7 
23. Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156:69-70 
24. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine 
FS (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151 (4):346-357 
25. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, 
Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Breast, Ovarian Cancer Susceptibility C, Fletcher O, Peto J, 
Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, 
Meijers-Heijboer H, Adank M, Hereditary B, Ovarian Cancer Research Group N, van der Luijt RB, Hein R, Dahmen N, 
Beckman L, Meindl A, Schmutzler RK, Muller-Myhsok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, 
Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LF, Haiman CA, 
Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, 
21 
 
 
Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys 
D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guenel P, Truong T, Laurent-Puig 
P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JI, Pita G, Alonso MR, Cox A, Brock IW, 
Cross SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, 
Knight JA, Glendon G, Mulligan AM, kConFab I, Australian Ovarian Cancer Study G, Lindblom A, Margolin S, Hooning MJ, 
Hollestelle A, van den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, 
Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Muller H, Arndt V, Stegmaier C, Swerdlow A, 
Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labreche F, Dumont M, Winqvist R, Pylkas 
K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T, Network G, Radice P, Peterlongo P, Manoukian S, 
Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, 
Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dork T, Kristensen VN, Anton-
Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng 
CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, 
Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen CY, Hsiung CN, Wu PE, Ding SL, 
Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole 
M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF (2013) Large-
scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45 (4):353-361, 361e351-352. 
doi:10.1038/ng.2563 
26. Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvanen AC, Naume B, Borresen-Dale AL, Kristensen VN (2008) 
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and 
germline haplotypes in breast cancer patients. Genes Chromosomes Cancer 47 (8):680-696. doi:10.1002/gcc.20569 
27. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, 
Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, 
Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R (2007) A recurrent mutation in PALB2 in 
Finnish cancer families. Nature 446 (7133):316-319. doi:10.1038/nature05609 
28. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys 
SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D, Breast 
Cancer Family R (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, 
interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6 (4):R375-
389. doi:10.1186/bcr801 
29. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Wijers-Koster PM, Blom 
JC, Pooley KA, Klijn JG, Tollenaar RA, Devilee P, van Asperen CJ (2007) Clinical correlates of low-risk variants in FGFR2, 
TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9 (6):R78. 
doi:10.1186/bcr1793 
30. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-
Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME 
(2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95 (1):123-129. 
doi:10.1038/sj.bjc.6603207 
31. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben 
R, Wareham N, Ahmed S, Healey CS, Bowman R, collaborators S, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le 
Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, 
Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, 
Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, 
Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, 
Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, 
MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, 
Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, 
Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, kConFab, Group AM, Mannermaa A, Kosma 
VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA (2007) Genome-wide association study identifies novel breast 
cancer susceptibility loci. Nature 447 (7148):1087-1093. doi:10.1038/nature05887 
22 
 
 
32. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, 
Stiger F, Persson I, Baron J, Weiderpass E (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast 
cancer risk: a case control study. Breast Cancer Res 6 (4):R437-449. doi:10.1186/bcr811 
33. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, 
Bhattacharyya NP, Cox A (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J 
Natl Cancer Inst 96 (24):1866-1869. doi:10.1093/jnci/dji001 
34. Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL, Luben R, Wareham NJ, Easton DF, Dunning AM, Ponder 
BA (2005) Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 
14 (16):2349-2356. doi:10.1093/hmg/ddi237 
35. Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Bruning T, Ko Y, Benner A, Wichmann 
HE, Brauch H, Hamann U, Network G (2005) German populations with infrequent CHEK2*1100delC and minor 
associations with early-onset and familial breast cancer. Eur J Cancer 41 (18):2896-2903. doi:10.1016/j.ejca.2005.04.049 
36. Jakubowska A, Jaworska K, Cybulski C, Janicka A, Szymanska-Pasternak J, Lener M, Narod SA, Lubinski J, Group IH-BCS 
(2009) Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 45 (5):837-842. 
doi:10.1016/j.ejca.2008.10.021 
37. Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin 
AK, Ambrosone C, Winqvist R, Brauch H, consortium G, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A, Beckmann 
MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM, Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, 
Sinn HP, Konstantopoulou I, Fostira F, Pectasides D, Dimopoulos AM, Fountzilas G, Clarke CL, Balleine R, Olson JE, 
Fredericksen Z, Diasio RB, Pathak H, Ross E, Weaver J, Rudiger T, Forsti A, Dunnebier T, Ademuyiwa F, Kulkarni S, Pylkas 
K, Jukkola-Vuorinen A, Ko YD, Van Limbergen E, Janssen H, Peto J, Fletcher O, Giles GG, Baglietto L, Verhoef S, Tomlinson 
I, Kosma VM, Beesley J, Greco D, Blomqvist C, Irwanto A, Liu J, Blows FM, Dawson SJ, Margolin S, Mannermaa A, Martin 
NG, Montgomery GW, Lambrechts D, dos Santos Silva I, Severi G, Hamann U, Pharoah P, Easton DF, Chang-Claude J, 
Yannoukakos D, Nevanlinna H, Wang X, Couch FJ (2011) Common breast cancer susceptibility loci are associated with 
triple-negative breast cancer. Cancer Res 71 (19):6240-6249. doi:10.1158/0008-5472.CAN-11-1266 
38. Swerdlow AJ, Jones ME, Schoemaker MJ, Hemming J, Thomas D, Williamson J, Ashworth A (2011) The Breakthrough 
Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology. Br J Cancer 105 (7):911-
917. doi:10.1038/bjc.2011.337 
39. Leu M, Humphreys K, Surakka I, Rehnberg E, Muilu J, Rosenstrom P, Almgren P, Jaaskelainen J, Lifton RP, Kyvik KO, 
Kaprio J, Pedersen NL, Palotie A, Hall P, Gronberg H, Groop L, Peltonen L, Palmgren J, Ripatti S (2010) NordicDB: a Nordic 
pool and portal for genome-wide control data. Eur J Hum Genet 18 (12):1322-1326. doi:10.1038/ejhg.2010.112 
40. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes 
D, Warren-Perry M, Tapper W, Eccles D, Evans DG, Breast Cancer Susceptibility C, Hooning M, Schutte M, van den 
Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF (2010) 
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42 (6):504-507. 
doi:10.1038/ng.586 
41. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, Stricker BH, Tiemeier H, Uitterlinden AG, 
Vingerling JR, Witteman JC (2009) The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 24 (9):553-
572. doi:10.1007/s10654-009-9386-z 
42. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, 
Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Australian Breast Cancer Tissue Bank I, Baglietto L, Bandera EV, 
Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter 
JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, 
Dunning AM, Durcan L, Ekici AB, Fasching PA, Familial Breast Cancer S, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, 
Flesch-Janys D, Gaudet MM, Consortium G, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, 
Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto 
A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, 
Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, 
Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, 
Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, 
23 
 
 
Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, 
Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, 
Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-
Closas M, Kraft P, Haiman CA, Vachon CM (2012) A meta-analysis of genome-wide association studies of breast cancer 
identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21 (24):5373-5384. doi:10.1093/hmg/dds381 
43. Ahsan H, Halpern J, Kibriya MG, Pierce BL, Tong L, Gamazon E, McGuire V, Felberg A, Shi J, Jasmine F, Roy S, Brutus R, 
Argos M, Melkonian S, Chang-Claude J, Andrulis I, Hopper JL, John EM, Malone K, Ursin G, Gammon MD, Thomas DC, 
Seminara D, Casey G, Knight JA, Southey MC, Giles GG, Santella RM, Lee E, Conti D, Duggan D, Gallinger S, Haile R, 
Jenkins M, Lindor NM, Newcomb P, Michailidou K, Apicella C, Park DJ, Peto J, Fletcher O, dos Santos Silva I, Lathrop M, 
Hunter DJ, Chanock SJ, Meindl A, Schmutzler RK, Muller-Myhsok B, Lochmann M, Beckmann L, Hein R, Makalic E, 
Schmidt DF, Bui QM, Stone J, Flesch-Janys D, Dahmen N, Nevanlinna H, Aittomaki K, Blomqvist C, Hall P, Czene K, Irwanto 
A, Liu J, Rahman N, Turnbull C, Familial Breast Cancer S, Dunning AM, Pharoah P, Waisfisz Q, Meijers-Heijboer H, 
Uitterlinden AG, Rivadeneira F, Nicolae D, Easton DF, Cox NJ, Whittemore AS (2014) A genome-wide association study of 
early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for 
breast cancer at any age. Cancer Epidemiol Biomarkers Prev 23 (4):658-669. doi:10.1158/1055-9965.EPI-13-0340 
44. Fu Z, Deming SL, Fair AM, Shrubsole MJ, Wujcik DM, Shu XO, Kelley M, Zheng W (2011) Well-done meat intake and 
meat-derived mutagen exposures in relation to breast cancer risk: the Nashville Breast Health Study. Breast Cancer Res 
Treat 129 (3):919-928. doi:10.1007/s10549-011-1538-7 
 
Table 1: The associations between T2D genetic risk score and breast cancer risk in Breast Cancer Association 
Consortium  
 T2D GRS by Quintiles Linear 
Trend  Q1 (low) Q2 Q3 Q4 Q5 
Overall Breast Cancer 
    Ncases/Ncontrols 9148/8497 9519/8496 9175/8496 9227/8496 9256/8497  
    OR
a
 [95% CI] 1 (reference) 1.03 (0.98,1.08) 1.00 (0.95,1.04) 1.00 (0.96,1.05) 1.00 (0.96,1.05) 0.69 
       
ER+ Breast Cancer 
    Ncases/Ncontrols 5473/8497 5616/8496 5259/8496 5351/8496 5375/8497  
    OR
a
 [95% CI] 1 (reference) 1.03 (0.98,1.09) 0.98 (0.93,1.03) 1.00 (0.95,1.05) 1.01 (0.96,1.06) 0.74 
       
ER- Breast Cancer 
    Ncases/Ncontrols 1402/8497 1490/8496 1451/8496 1451/8496 1494/8497  
    OR
a
 [95% CI] 1 (reference) 1.03 (0.95,1.12) 1.00 (0.92,1.10) 0.97 (0.89,1.06) 0.99 (0.91,1.08) 0.47 
 
Among Pre-menopausal Women 
    Ncases/Ncontrols 1971/1881 2152/1770 2023/1796 2018/1824 2045/1782  
    OR
a
 [95% CI] 1 (reference) 1.11 (1.00,1.24) 1.06 (0.95,1.18) 1.06 (0.95,1.17) 1.05 (0.94,1.17) 0.74 
 
Among Post-menopausal Women 
    Ncases/Ncontrols 4751/3909 4817/3874 4514/3909 4455/3821 4532/3842  
    OR
a
 [95% CI] 1 (reference) 1.03 (0.97,1.10) 0.99 (0.93,1.06) 0.98 (0.92,1.05) 1.02 (0.96,1.09) 0.93 
       
 
Among Age<50 Women 
    Ncases/Ncontrols 1757/2389 1941/2375 1919/2372 1843/2363 1926/2393  
    OR
a
 [95% CI] 1 (reference) 1.07 (0.97,1.18) 1.07 (0.97,1.19) 1.04 (0.94,1.15) 1.04 (0.94,1.15) 0.74 
       
 
Among Age≥50 Women 
    Ncases/Ncontrols 7391/6108 7578/6121 7256/6124 7384/6133 7330/6104  
    OR
a
 [95% CI] 1 (reference) 1.01 (0.96,1.07) 0.98 (0.93,1.03) 1.00 (0.95,1.05) 1.00 (0.95,1.05) 0.62 
       
 
Among BMI<25 Women 
    Ncases/Ncontrols 2420/2150 2526/2103 2418/2146 2321/2187 2485/2168  
    OR
a
 [95% CI] 1 (reference) 1.05 (0.96,1.15) 0.99 (0.90,1.09) 0.94 (0.86,1.03) 1.04 (0.95,1.14) 0.64 
       
 
Among BMI≥25 Women 
    Ncases/Ncontrols 2499/2154 2652/2308 2552/2282 2611/2229 2651/2359  
    OR
a
 [95% CI] 1 (reference) 1.00 (0.92,1.09) 0.97 (0.89,1.06) 1.03 (0.94,1.12) 0.96 (0.88,1.05) 0.64 
       
T2D GRS: Weighted type 2 diabetes related genetic variants risk score 
a
: All associations were assessed individually by each study and then combined by fixed-effect inverse-variance weighted meta-
analysis. All models adjusted for age and top eight principal components for population stratification. Study specific principal 
component was further adjusted for LMBC study. 
 
 
Table 2: Selected T2D risk variants associated with breast cancer risk in BCAC at P < 0.05 and their associations in GAME-ON DRIVE project 
   
 
   
BCAC 
(Cases N=46325/ Controls N=42482)  
GAME-ON DRIVE 
(Cases N=16003/ Controls N=41335)  
Combined 
(Cases N=62328/ Controls 
N=83817) 
SNPs Chr Positiona Geneb Allelesc R-squared 
 
RAFe ORf 95% CIf P-Valuef 
 
RAF OR 95% CI P-Value 
 
ORg 95% CIg P-Valueg 
rs243021 2 60584819 BCL11A A/G - 
 
0.46 1.02 (1.00,1.04) 0.03 
 
0.46 1.01 (0.98,1.05) 0.45 
 
1.02 (1.00,1.04) 0.02 
rs4402960 3 185511687 IGF2BP2 T/G - 
 
0.31 0.98 (0.96,1.00) 0.05 
 
0.32 0.97 (0.94,1.01) 0.13 
 
0.98 (0.96,1.00) 0.01 
rs13292136 9 81952128 CHCHD9 C/T 0.926 
 
0.92 1.05 (1.01,1.09) 0.02 
 
0.94 0.98 (0.92,1.05) 0.62 
 
1.03 (0.99,1.06) 0.08 
rs7903146 10 114758349 TCF7L2 T/C - 
 
0.28 1.04 (1.02,1.07) 1.20E-4 
 
0.30 1.04 (1.00,1.08) 0.04 
 
1.04 (1.02,1.06) 1.26E-05 
rs7961581 12 71663102 TSPAN8,LGR5 C/T 0.981 
 
0.28 0.97 (0.94,0.99) 2.48E-3 
 
0.26 1.00 (0.96,1.04) 0.96 
 
0.97 (0.95,0.99) 9.01E-03 
rs8042680 15 91521337 PRC1 A/C - 
 
0.31 0.98 (0.95,1.00) 0.02 
 
0.30 0.95 (0.92,0.99) 6.18E-3 
 
0.97 (0.95,0.99) 8.05E-04 
rs9939609 16 53820527 FTO A/T 1.000   0.40 0.93 (0.91,0.95) 3.63E-12   0.38 0.96 (0.93,0.99) 0.01   0.94 (0.92,0.95) 4.13E-13 
SNP: single nucleotide polymorphism; Chr: Chromosome; BCAC: Breast Cancer Association Consortium; GAME-ON: Genetic Associations and Mechanisms in Oncology; DRIVE: Discovery, Biology, and Risk of Inherited 
Variants in Breast Cancer; RAF: risk allele frequency; OR: odds ratio; CI: confidence interval;  
a: The chromosome physical position is based on the National Center for Biotechnology Information (NCBI) database, Build 36.3.  
b: The closest gene.  
c: Risk/reference alleles. The risk allele is the allele that associated with increased risk of type 2 diabetes. 
d: Imputation quality in BCAC; - indicates directly genotyped SNPs. 
e: Among controls. 
f: All associations were assessed individually by each study and then combined by a fixed-effects inverse-variance weighted meta-analysis. All models adjusted for first eight principal components for population 
stratification. Study specific principal component was further adjusted for LMBC study. 
g: Combined BCAC and GAME-ON DRIVE results by fixed-effects inverse-variance weighted meta-analysis. 
 
 
Identified 88 SNPs associated with type 2 diabetes from the NHGRI 
GWAS catalog  (P< 5 × 10-8, Accessed 11/19/2012) 
50 SNPs were identified from European ancestry, representing 33 
independent loci (LD R2<0.1) 
The T2D genetic risk score was constructed by using these 33 SNPs 
in the formula: 𝑤𝑖𝑆𝑁𝑃𝑖
33
𝑖=1  , where 𝑤𝑖 is the logarithm of the odds 
ratio of the ith SNP with T2D, as reported in the GWAS, and 𝑆𝑁𝑃𝑖  is 
the number risk alleles carried by a given subject on the ith SNP 
The SNP having the smallest p-value (with T2D, reported in previous 
T2D GWASs) in each locus was selected to represent the locus  
Availability in BCAC 
22 SNPs were Imputed with 
the 1000 Genome Project 
Phase I integrated variant 
set as reference using the 
IMPUTE2 software 
11 SNPs were directly 
genotyped using a custom 
Illumina iSelect genotyping 
array (iCOGS) 
 
